《COVID-19 指南：由新型冠状病毒 SARS-CoV-2 引起的全球大流行》。
A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
机构信息
Department of Biological Sciences, Vanderbilt University, Nashville, TN, USA.
出版信息
FEBS J. 2020 Sep;287(17):3633-3650. doi: 10.1111/febs.15375. Epub 2020 Jun 16.
Abstract
The emergence of the SARS-CoV-2 strain of the human coronavirus has thrown the world into the midst of a new pandemic. In the human body, the virus causes COVID-19, a disease characterized by shortness of breath, fever, and pneumonia, which can be fatal in vulnerable individuals. SARS-CoV-2 has characteristics of past human coronaviruses, with close genomic similarities to SARS-CoV, the virus that causes the disease SARS. Like these related coronaviruses, SARS-CoV-2 is transmitted through the inhalation of droplets and interaction with contaminated surfaces. Across the world, laboratories are developing candidate vaccines for the virus - with vaccine trials underway in the United States and the United Kingdom - and considering various drugs for possible treatments and prophylaxis. Here, we provide an overview of SARS-CoV-2 by analyzing its virology, epidemiology, and modes of transmission while examining the current progress of testing procedures and possible treatments through drugs and vaccines.
摘要
新型冠状病毒 SARS-CoV-2 的出现使世界陷入了新的大流行之中。在人体中，该病毒会引起 COVID-19，这是一种以呼吸急促、发热和肺炎为特征的疾病，在易感染人群中可能是致命的。SARS-CoV-2 具有过去人类冠状病毒的特征，与导致 SARS 疾病的 SARS-CoV 病毒在基因组上非常相似。与这些相关的冠状病毒一样，SARS-CoV-2 通过吸入飞沫和与受污染表面的相互作用传播。在世界各地，实验室正在开发针对该病毒的候选疫苗 - 美国和英国正在进行疫苗试验 - 并考虑使用各种药物进行可能的治疗和预防。在这里，我们通过分析 SARS-CoV-2 的病毒学、流行病学和传播方式，同时检查通过药物和疫苗进行的检测程序和可能治疗方法的最新进展，对其进行了概述。
相似文献
1
A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.《COVID-19 指南：由新型冠状病毒 SARS-CoV-2 引起的全球大流行》。
FEBS J. 2020 Sep;287(17):3633-3650. doi: 10.1111/febs.15375. Epub 2020 Jun 16.
2
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.具有治疗新型呼吸道 2019 冠状病毒潜力的化合物。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.00399-20.
3
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.洛匹那韦疗法治疗严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒的系统评价——为新型冠状病毒病治疗方案提供参考。
J Med Virol. 2020 Jun;92(6):556-563. doi: 10.1002/jmv.25729. Epub 2020 Mar 12.
4
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.用于 SARS-CoV-2 治疗的潜在抗病毒药物：临床前发现和正在进行的临床研究。
In Vivo. 2020 Jun;34(3 Suppl):1597-1602. doi: 10.21873/invivo.11949.
5
Remdesivir against COVID-19 and Other Viral Diseases.瑞德西韦治疗 COVID-19 及其他病毒性疾病。
Clin Microbiol Rev. 2020 Oct 14;34(1). doi: 10.1128/CMR.00162-20. Print 2020 Dec 16.
6
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.抗 SARS-CoV-2 再利用抗病毒药物的临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
7
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.当前用于管理新型冠状病毒病 2019（COVID-19）的药理学方法及其利用的原理：综述。
Rev Med Virol. 2020 Sep;30(5):e2136. doi: 10.1002/rmv.2136. Epub 2020 Jul 9.
8
Race to find COVID-19 treatments accelerates.寻找新冠病毒治疗方法的竞赛加速。
Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.
9
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.新型冠状病毒治疗药物的安全性、临床应用和抗病毒研究概述。
J Infect Public Health. 2020 Oct;13(10):1405-1414. doi: 10.1016/j.jiph.2020.07.004. Epub 2020 Jul 13.
10
Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.从过敏学家的角度看 COVID-19 的分子机制和流行病学。
J Allergy Clin Immunol. 2020 Aug;146(2):285-299. doi: 10.1016/j.jaci.2020.05.033. Epub 2020 Jul 2.
引用本文的文献
1
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）感染不影响接受嵌合抗原受体（CAR）T细胞疗法治疗的复发/难治性大B细胞淋巴瘤患者的治疗结果。
Ann Hematol. 2025 Jun 4. doi: 10.1007/s00277-025-06425-8.
2
Dynamic brain glymphatic changes and cognitive function in COVID-19 recovered patients: a DTI-ALPS prospective cohort study.新冠康复患者的脑类淋巴系统动态变化与认知功能：一项扩散张量成像-动脉自旋标记前瞻性队列研究
Front Psychol. 2025 Apr 22;16:1465660. doi: 10.3389/fpsyg.2025.1465660. eCollection 2025.
3
Impact of obstructive sleep apnea on inpatient outcomes of COVID-19: a propensity-score matching analysis of the US Nationwide Inpatient Sample 2020.阻塞性睡眠呼吸暂停对COVID-19住院患者预后的影响：一项对2020年美国全国住院患者样本的倾向评分匹配分析。
Front Med (Lausanne). 2025 Mar 20;12:1472176. doi: 10.3389/fmed.2025.1472176. eCollection 2025.
4
Advances in Virus Biorecognition and Detection Techniques for the Surveillance and Prevention of Infectious Diseases.用于传染病监测与预防的病毒生物识别及检测技术进展
Biosensors (Basel). 2025 Mar 20;15(3):198. doi: 10.3390/bios15030198.
5
Impact of COVID-19 on orthopedic trauma patients from 2021 to 2022 when restrictions were lifted, compared with the pre-pandemic period.与疫情前时期相比，2021年至2022年限制解除时COVID-19对骨科创伤患者的影响。
J Orthop Surg Res. 2025 Feb 12;20(1):158. doi: 10.1186/s13018-025-05554-0.
6
Impact of Vaccination Status on COVID-19 Severity and Pulmonary Involvement.疫苗接种状况对COVID-19严重程度和肺部受累情况的影响。
Medicina (Kaunas). 2024 Nov 22;60(12):1919. doi: 10.3390/medicina60121919.
7
Unilateral Anterior Scleritis Following the Booster Shot of Inactivated COVID-19 (Sinopharm) Vaccine in a 52-Year-Old Woman: A Case Report.一名52岁女性在接种新冠病毒灭活疫苗（国药集团）加强针后出现单侧前巩膜炎：病例报告
Case Rep Rheumatol. 2024 Dec 28;2024:6614757. doi: 10.1155/crrh/6614757. eCollection 2024.
8
Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal study.解读HIV-1/SARS-CoV-2合并感染的长期免疫效应：一项纵向研究。
Med Microbiol Immunol. 2024 Dec 26;214(1):4. doi: 10.1007/s00430-024-00813-z.
9
The value of using COVID-19 antibody tests as a potential approach to prioritize vaccination delivery.利用 COVID-19 抗体检测作为优先提供疫苗接种的潜在方法的价值。
PLoS One. 2024 Oct 16;19(10):e0311881. doi: 10.1371/journal.pone.0311881. eCollection 2024.
10
Dynamics of anti-SARS-CoV-2 antibodies in the Albanian population: Impact of infection- and vaccine-induced immunity during the COVID-19 pandemic.阿尔巴尼亚人群中抗SARS-CoV-2抗体的动态变化：新冠疫情期间感染和疫苗诱导免疫的影响
IJID Reg. 2024 Sep 5;13:100440. doi: 10.1016/j.ijregi.2024.100440. eCollection 2024 Dec.
本文引用的文献
1
The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020.2019新型冠状病毒病（COVID-19）疫情的流行病学特征 - 中国，2020年
China CDC Wkly. 2020 Feb 21;2(8):113-122.
2
Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan.目前在日本正在进行的针对新冠病毒疾病治疗的主要临床试验以及正在开展或计划开展的研究。
Glob Health Med. 2020 Apr 30;2(2):96-101. doi: 10.35772/ghm.2020.01034.
3
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.I 型干扰素易感性区分 SARS-CoV-2 和 SARS-CoV。
J Virol. 2020 Nov 9;94(23). doi: 10.1128/JVI.01410-20.
4
Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19.羟氯喹在美国 COVID-19 住院患者中的使用效果。
Med. 2020 Dec 18;1(1):114-127.e3. doi: 10.1016/j.medj.2020.06.001. Epub 2020 Jun 5.
5
Comparison of Two Commercial Molecular Tests and a Laboratory-Developed Modification of the CDC 2019-nCoV Reverse Transcriptase PCR Assay for the Detection of SARS-CoV-2.两种商业分子检测方法与一种实验室开发的对疾病控制与预防中心（CDC）2019新型冠状病毒逆转录聚合酶链反应（PCR）检测法的改良方法用于检测严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的比较
J Clin Microbiol. 2020 Jul 23;58(8). doi: 10.1128/JCM.00938-20.
6
A serological assay to detect SARS-CoV-2 seroconversion in humans.用于检测人类 SARS-CoV-2 血清转化的血清学检测方法。
Nat Med. 2020 Jul;26(7):1033-1036. doi: 10.1038/s41591-020-0913-5. Epub 2020 May 12.
7
A human monoclonal antibody blocking SARS-CoV-2 infection.一种人源单克隆抗体阻断 SARS-CoV-2 感染。
Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.
8
Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.CRISPR 作为抗病毒策略的发展，以对抗 SARS-CoV-2 和流感。
Cell. 2020 May 14;181(4):865-876.e12. doi: 10.1016/j.cell.2020.04.020. Epub 2020 Apr 29.
9
Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020.2020 年 3 月用于严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的血清学检测。
Euro Surveill. 2020 Apr;25(16). doi: 10.2807/1560-7917.ES.2020.25.16.2000421.
10
The trinity of COVID-19: immunity, inflammation and intervention.COVID-19 的三位一体：免疫、炎症和干预。
Nat Rev Immunol. 2020 Jun;20(6):363-374. doi: 10.1038/s41577-020-0311-8. Epub 2020 Apr 28.
Zotero 插件